Vera Therapeutics' atacicept wins FDA accelerated approval for IgAN, entering a competitive market alongside Otsuka's Voyxact with a dual APRIL/BAFF mechanism.
July 7, 2026 02:10 PM EDT
PharmaFDA+
Vera's IgAN approval kicks off competition with Otsuka
Nicole DeFeudis
Vera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys.
FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka
FDA approves Vera Therapeutics kidney disease treatment
What's Going on with Vera Therapeutics Stock on Monday? - Vera Therapeutics (NASDAQ:VERA)
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
Why Is Vera Therapeutics Stock Gaining Tuesday? - Vera Therapeutics (NASDAQ:VERA)
First-in-Class Drug Approved for IgA Nephropathy
Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
Boom Times For Autoimmune Disease Therapies
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no…
Otsuka's Voyxact preserved kidney function over 12 months in IgA nephropathy patients, new eGFR data show, as the company pursues…
The data are crucial to Otsuka’s bid to get a full approval for Voyxact, as rival Vera's atacicept awaits a July 7 decision.
The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney…
Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors weigh trial data and competition…
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s…
